{"id":60960,"date":"2024-02-28T07:18:14","date_gmt":"2024-02-28T07:18:14","guid":{"rendered":"https:\/\/medsname.com\/trinicalm-plus\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"trinicalm-plus","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/trinicalm-plus\/","title":{"rendered":"Trinicalm Plus"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Trinicalm Plus?<\/h3>\n
\n

Trinicalm Plus<\/strong> contains a fixed-dose combination of trifluoperazine 5 mg + trihexyphenidyl 2 mg<\/strong> from a WHO-GMP certified manufacturer (Tripada Healthcare) — a first-generation antipsychotic<\/strong> (D2<\/sub> antagonist) paired with an anticholinergic anti-Parkinson agent<\/strong> to pre-empt the extrapyramidal side effects (EPS — parkinsonism, dystonia, akathisia) that high-potency typical antipsychotics commonly cause. Used primarily in countries where typical antipsychotics remain in regular use for schizophrenia and severe anxiety\/agitation. Important warnings<\/strong>: trifluoperazine carries the FDA avertizare cutie neagr\u0103 pentru mortalitate la v\u00e2rstnici cu demen\u021b\u0103<\/strong>, plus high tardive dyskinesia and neuroleptic malignant syndrome risks; trihexyphenidyl has anticholinergic side effects (cognitive impairment, urinary retention, falls in elderly) and recognised abuse potential<\/strong> (sought for its euphoric \/ stimulant effect at supratherapeutic doses).<\/p>\n<\/div>\n

\nCe beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate ale clien\u021bilor<\/a>\n<\/div>\n

\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n

De ce s\u0103 comanzi de la MedsBase<\/h3>\n

Medicamentele noastre generice sunt procurate de la produc\u0103tori certifica\u021bi WHO-GMP \u0219i expediate la nivel mondial \u00een ambalaje discrete \u0219i simple \u2014 f\u0103r\u0103 denumirea medicamentului pe exteriorul coletului. Pl\u0103\u021bile cu cardul sunt procesate printr-un procesor reglementat (descrierile de pe extrasul de cont includ un procesor de pl\u0103\u021bi cu card reglementat \u2014 niciodat\u0103 \u201cMedsBase\u201d sau numele vreunui medicament). Accept\u0103m \u0219i criptomonede \u0219i transferuri bancare SEPA. Fiecare comand\u0103 este sus\u021binut\u0103 de Politica noastr\u0103 de Asigurare pentru Relivrare.<\/p>\n<\/div>\n

Important \u2014 acesta nu este un medicament pentru anxietate situa\u021bional\u0103.<\/strong> Trinicalm Plus is a first-generation antipsychotic combined with an anticholinergic anti-Parkinson agent<\/strong>, prescris \u0219i titrat pe s\u0103pt\u0103m\u00e2ni pentru schizophrenia and other psychotic disorders, severe anxiety \/ agitation in some legacy regimens, with prophylactic coverage of antipsychotic-induced extrapyramidal symptoms (EPS)<\/strong>. Este prime\u0219te,<\/strong> medicamentul potrivit pentru anxietatea acut\u0103 legat\u0103 de performan\u021b\u0103 (zbor, vorbire \u00een public, examene) \u2014 pentru acele cazuri, beta-blocantele (propranolol), benzodiazepinele sau hidroxizina sunt op\u021biuni clinice adecvate. Dac\u0103 nu ave\u021bi o tulburare de dispozi\u021bie, anxietate sau psihiatric\u0103 diagnosticat\u0103, nu \u00eencepe\u021bi acest tratament.<\/div>\n
Avertizare cutie neagr\u0103 FDA \u2014 mortalitate la v\u00e2rstnici cu demen\u021b\u0103.<\/strong> Toate antipsihoticele (atipice \u0219i conven\u021bionale) poart\u0103 o avertizare cutie neagr\u0103 FDA pentru mortalitate crescut\u0103 atunci c\u00e2nd sunt utilizate pentru tratarea psihozei sau tulbur\u0103rilor de comportament legate de demen\u021b\u0103 la pacien\u021bii v\u00e2rstnici. Acest medicament este neaprobat<\/strong> pentru simptome legate de demen\u021b\u0103.<\/div>\n

What Is Trinicalm Plus?<\/h2>\n

Trinicalm Plus is an oral tablet of trifluoperazine 5 mg + trihexyphenidyl 2 mg<\/strong> in fixed-dose combination, manufactured by Tripada Healthcare. The combination addresses a long-standing problem with first-generation antipsychotics: high-potency D2<\/sub> antagonists like trifluoperazine routinely cause extrapyramidal side effects (drug-induced parkinsonism, akathisia, acute dystonia) that limit tolerability and adherence. Co-prescribing an anticholinergic anti-Parkinson agent like trihexyphenidyl mitigates these motor side effects.<\/p>\n

This is a second-line approach in modern psychiatry<\/strong> — first-line is to use an atypical antipsychotic (which has lower EPS risk and does not require routine anticholinergic cover). The combination remains common in countries where typical antipsychotics are first-line for cost or availability reasons.<\/p>\n

Component Drugs<\/h2>\n

What each component does<\/h2>\n\n\n\n\n\n\n
Component<\/th>\nClas\u0103<\/th>\nMecanism de ac\u021biune<\/th>\nRole in this combination<\/th>\n<\/tr>\n<\/thead>\n
Trifluoperazine 5 mg<\/td>\nFirst-generation phenothiazine antipsychotic (high-potency)<\/td>\nTight D2<\/sub> antagonism in mesolimbic, mesocortical, nigrostriatal, and tuberoinfundibular pathways<\/td>\nPrimary antipsychotic action; also approved for short-term treatment of severe non-psychotic anxiety not responsive to usual measures (legacy indication)<\/td>\n<\/tr>\n
Trihexyphenidyl 2 mg<\/td>\nCentrally-acting anticholinergic anti-Parkinson agent<\/td>\nM1 muscarinic antagonism in the basal ganglia, restoring acetylcholine \/ dopamine balance<\/td>\nPre-empts and treats trifluoperazine-induced parkinsonism, dystonia, and akathisia<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Indica\u021bii aprobate<\/h2>\n
    \n
  • Schizophrenia and other psychotic disorders<\/strong> requiring trifluoperazine therapy with prophylactic EPS coverage<\/li>\n
  • Severe anxiety \/ agitation<\/strong> not responsive to standard treatment (legacy trifluoperazine indication; first-line modern alternatives are SSRIs and atypical antipsychotics)<\/li>\n<\/ul>\n

    Doza<\/h2>\n\n\n\n\n\n\n\n
    Indica\u021bie<\/th>\nDoza tipic\u0103<\/th>\nMaximum<\/th>\nNote<\/th>\n<\/tr>\n<\/thead>\n
    Schizophrenia \/ psychosis<\/td>\n1 tablet (5\/2) BID–TID<\/td>\n3 tablets (15 mg trifluoperazine + 6 mg trihexyphenidyl) per day<\/td>\nTrifluoperazine total 5–15 mg\/day in fixed combination; higher trifluoperazine doses require separate dosing<\/td>\n<\/tr>\n
    Severe anxiety<\/td>\n1 tablet BID<\/td>\n2 tablets\/day<\/td>\nShort-term only — weeks rather than months; reassess for switch to SSRI \/ SNRI<\/td>\n<\/tr>\n
    V\u00e2rstnici<\/td>\n½ tablet BID if combination is unavoidable<\/td>\n\u2014<\/td>\nHigh EPS, anticholinergic, and falls risk; black-box dementia warning<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Side Effects (by Component)<\/h2>\n

    Trifluoperazine side effects<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n
    Mecanism de ac\u021biune<\/th>\nEfecte<\/th>\nNote<\/th>\n<\/tr>\n<\/thead>\n
    D2<\/sub> blockade (nigrostriatal)<\/td>\nAcute dystonia (eye-rolling, torticollis, jaw clenching), parkinsonism (tremor, rigidity, bradykinesia), akathisia (inner restlessness), tardive dyskinesia (long-term involuntary movements)<\/td>\nHigh risk — the reason trihexyphenidyl is co-prescribed; tardive dyskinesia can be irreversible and develops with long-term exposure<\/td>\n<\/tr>\n
    D2<\/sub> blockade (tuberoinfundibular)<\/td>\nHyperprolactinaemia (galactorrhoea, gynaecomastia, amenorrhoea, sexual dysfunction)<\/td>\nCommon with high-potency typicals<\/td>\n<\/tr>\n
    H1<\/sub> blocare<\/td>\nSedare<\/td>\nLess than chlorpromazine<\/td>\n<\/tr>\n
    Blocare alfa-1<\/td>\nHipotensiune ortostatic\u0103<\/td>\nLess than chlorpromazine<\/td>\n<\/tr>\n
    Prelungirea intervalului QT<\/td>\nCardiac arrhythmia risk<\/td>\nECG de baz\u0103; precau\u021bie cu alte medicamente care prelungesc intervalul QT<\/td>\n<\/tr>\n
    Altele<\/td>\nPhotosensitivity, ocular changes, jaundice<\/td>\nPreocup\u0103ri pe termen lung<\/td>\n<\/tr>\n
    Rare, dar grave<\/td>\nNeuroleptic malignant syndrome (hyperthermia, rigidity, autonomic instability, altered mental status)<\/td>\nMedical emergency<\/td>\n<\/tr>\n
    Rare<\/td>\nLowered seizure threshold<\/td>\nCaution in epilepsy<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Trihexyphenidyl side effects<\/h2>\n\n\n\n\n\n\n\n\n
    Mecanism de ac\u021biune<\/th>\nEfecte<\/th>\nNote<\/th>\n<\/tr>\n<\/thead>\n
    Peripheral anticholinergic<\/td>\nDry mouth, blurred vision, constipation, urinary retention<\/td>\nCommon; particularly problematic with BPH<\/td>\n<\/tr>\n
    Central anticholinergic<\/td>\nConfusion, memory impairment, cognitive dulling, agitation<\/td>\nOlder adults at greatest risk — linked to long-term cognitive decline<\/td>\n<\/tr>\n
    Altele<\/td>\nTachycardia, dizziness, falls<\/td>\nFalls risk in elderly<\/td>\n<\/tr>\n
    Important<\/td>\nAbuse potential<\/strong><\/td>\nTrihexyphenidyl is sought at supratherapeutic doses for euphoric \/ stimulant \/ hallucinogenic effects; some jurisdictions have introduced controls. Patients with substance use history need monitoring<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Interac\u021biuni medicamentoase<\/h2>\n

    Prelungirea intervalului QT<\/strong>: avoid combination with other QT-prolonging drugs — ziprasidone, citalopram (high dose), methadone, ondansetron, fluoroquinolones.<\/p>\n

    Anticholinergic stacking<\/strong>: trihexyphenidyl already pushes anticholinergic burden — combine cautiously with TCAs, paroxetine, antihistamines, oxybutynin, hyoscyamine; in older adults this can produce confusion, falls, and urinary retention.<\/p>\n

    CNS depression<\/strong>: alcohol, benzodiazepines, opioids — additive sedation.<\/p>\n

    Antihipertensive<\/strong>: additive orthostasis.<\/p>\n

    Levodopa antagonism<\/strong>: trifluoperazine D2<\/sub> blockade reduces levodopa effect — problematic in Parkinson’s disease.<\/p>\n

    Why Modern Practice Often Avoids This Combination<\/h2>\n

    Where atypical antipsychotics are available and affordable, modern practice generally avoids first-generation antipsychotics + routine anticholinergic cover<\/strong> because:<\/p>\n